Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$14.04 USD
-0.22 (-1.54%)
Updated Sep 25, 2024 11:46 AM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 101 - 120 ( 729 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2: EXPAREL Excels Despite Headwinds; Progress Toward Product Expansion
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
2Q22: Solid Performance Excluding Resolved Manufacturing Hiccup; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Strong Q2 Prelim Sales Amid Pockets of Persistent Pandemic Headwinds
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
May Preliminary Sales: EXPAREL Shows Strong YoY Growth Going Into June
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
April Preliminary Sales: Looking to May for Growth to Pick Up Momentum
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
1Q22: Solid Q vs. Our Estimates; Industry Macro Headwinds Are Long-Term Exparel Tailwinds, In Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1: EXPAREL Growth In-tact Despite Market Headwinds; Pipeline Expansion
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Prelim Sales: Record March Exparel Sales Set the Tone for Growth in 2022
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
February Preliminary Sales Put EXPAREL Growth Back On-Track
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L